Clinical Trial: A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity

U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06976372) titled 'A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity' on May 09.

Brief Summary: The primary objective of this study is to assess the pharmacokinetics (PK) of AMG 133 after multiple subcutaneous (SC) administrations in participants with overweight or obesity using various dose regimens.

Study Start Date: Aug. 20, 2024

Study Type: INTERVENTIONAL

Condition: Overweight Obesity

Intervention: DRUG: AMG 133

AMG 133 will be administered SC. Dose levels range from A to D lowest to highest.

Recruitment Status: COMPLETED

Sponsor: Amgen

Published by HT Digital Content Services with permissi...